ClinicalTrials.gov Identifier: NCT01399957
Mount Sinai Rehabilitation Hospital
490 Blue Hills Ave
Hartford, CT 06112
Ampyra (dalfampridine) has been approved by the FDA for improving walking speed in persons with multiple sclerosis (MS). This observational study was designed to capture information on additional possible benefits person’s taking Ampyra may or may not experience. This project seeks to determine factors that will predict a response (an increase in walking speed) to dalfampridine. A second goal is to identify possible additional benefits to taking Dalfampridine.
Status Closed to enrollment, in data analysis phase only.
Principal Investigators Albert Lo, MD, PhD and Elizabeth Triche, PhD
Contact Name Kayla Olson, Study Coordinator
Phone (860) 714-3005